在ccRCC中,LRRK2通过激活LPCAT1来降低对TKI和PD-1阻塞的敏感性
Yulong Hong1,2, Wei Li1,2, Zhuo Xing1,2
1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Oncogene
|March 23, 2025
概括
LRRK2驱动清细胞细胞癌 (ccRCC) 的扩散,并降低对氨酸激酶抑制剂 (TKI) 和免疫检查点抑制剂 (ICI) 疗法的敏感性. 用LR-protac针对LRRK2可以提高ccRCC中的TKI和ICI治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- 用氨酸激酶抑制剂 (TKI) 和免疫检查点抑制剂 (ICI) 进行组合治疗是晚期清细胞细胞癌 (ccRCC) 的关键策略.
- 确定新的可用药物点对于提高当前ccRCC治疗的疗效至关重要.
研究的目的:
- 确定新的治疗目标,以改善ccRCC中的TKI和ICI组合疗法.
- 调查莱氏素丰富的重复激酶2 (LRRK2) 在ccRCC进展中的作用及其对治疗敏感性的影响.
主要方法:
- 分析公开的ccRCC数据集和蛋白激酶抑制剂数据,以确定潜在的目标.
- 研究LRRK2在ccRCC细胞增殖中的机制及其与脂质代谢调节器LPCAT1.1的相互作用.
- 开发和测试一种LR-protac分子以准酶独立LRRK2活性.
主要成果:
- 确定了LRRK2作为一个由HIF2A上调的目标,驱动ccRCC的扩散,独立于其酶活性.
- 发现LRRK2可以抑制LPCAT1降解,通过上调IL-1β.通过上调IL-1β.降低对TKI和PD-1阻塞的敏感性.
- 开发的LR-protac有效降低了LRRK2水平,并在ccRCC模型中增强了TKI和PD-1阻断的抗瘤作用.
结论:
- LRRK2是ccRCC扩散和对TKI和ICI疗法的耐药性的关键调解者.
- 通过LR-protac针对LRRK2的激酶独立功能是改善ccRCC治疗结果的有希望的策略.
更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.4K
11:31Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
9.9K
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:26Receptor Tyrosine Kinases
12.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.0K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K